Literature DB >> 21477010

Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course.

R B Warren1, C E Kleyn, W P Gulliver.   

Abstract

Psoriasis is associated with significant physical, psychological, social and economic burden, the cumulative effect of which may result in failure to achieve 'full life potential' in some patients, termed 'cumulative life course impairment' (CLCI). In this concept, the burden of stigmatization, and physical and psychological comorbidities (risk factors for cumulative impairment) and coping strategies and external factors (having potential moderating effects), interact to cause lifetime impairment. Components of CLCI are supported by cross-sectional data; however, the cumulative nature of impairment in patients with psoriasis is not yet established. Nonetheless, CLCI makes intuitive sense to many dermatologists who recognize the cumulative impact of psoriasis on the lives of some patients. This supplement explores the causes and mechanisms of CLCI qualitatively by presenting cases which are representative of typical patients with moderate-to-severe psoriasis. These cases demonstrate the effect of psoriasis in influencing major life-changing decisions and altering the course of patients' lives, preventing patients from attaining their life goals, pursuing their chosen career, gaining a desired educational level, developing social relationships, gaining full pleasure from family life or having children. All these patients believe that their lives would have taken a different course had they not had psoriasis. Additional research to determine how CLCI occurs and to identify the risk factors for cumulative impairment is required. Understanding the key risk factors for CLCI may help physicians identify patients who are more vulnerable to the cumulative impact of psoriasis, resulting in more appropriate treatment decisions earlier in the disease course.
© 2011 The Authors. BJD © 2011 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2011        PMID: 21477010     DOI: 10.1111/j.1365-2133.2011.10280.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  16 in total

Review 1.  Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment.

Authors:  Wolf-Henning Boehncke; Nicolo Costantino Brembilla
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

Review 2.  The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives.

Authors:  Steven R Feldman; Bernard Goffe; Gary Rice; Matthew Mitchell; Mandeep Kaur; Debbie Robertson; Debra Sierka; Jeffrey A Bourret; Tamara S Evans; Alice Gottlieb
Journal:  Am Health Drug Benefits       Date:  2016-12

3.  Safety of Systemic Agents for the Treatment of Pediatric Psoriasis.

Authors:  Inge M G J Bronckers; Marieke M B Seyger; Dennis P West; Irene Lara-Corrales; Megha Tollefson; Wynnis L Tom; Marcia Hogeling; Leah Belazarian; Claus Zachariae; Emmanuel Mahé; Elaine Siegfried; Sandra Philipp; Zsuzsanna Szalai; Ruth Ann Vleugels; Kristen Holland; Ruth Murphy; Eulalia Baselga; Kelly Cordoro; Jo Lambert; Alex Alexopoulos; Ulrich Mrowietz; Wietske Kievit; Amy S Paller
Journal:  JAMA Dermatol       Date:  2017-11-01       Impact factor: 10.282

4.  Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.

Authors:  Richard G B Langley; Kristian Reich; Vibeke Strand; Steven R Feldman; Carle Paul; Kenneth Gordon; Richard B Warren; Darryl Toth; Enkeleida Nikaï; Baojin Zhu; Orin Goldblum; Emily Edson-Heredia; Hilde Carlier; Russel Burge; Chen-Yen Lin; Kristin Hollister; Matthias Augustin
Journal:  Qual Life Res       Date:  2019-10-26       Impact factor: 4.147

5.  Association between moderate to severe psoriasis and periodontitis in a Scandinavian population.

Authors:  Rasa Skudutyte-Rysstad; Ellen Margrethe Slevolden; Bjørn Frode Hansen; Leiv Sandvik; Hans Ragnar Preus
Journal:  BMC Oral Health       Date:  2014-11-26       Impact factor: 2.757

6.  How does stigma affect people with psoriasis?

Authors:  Patryk Łakuta; Kamil Marcinkiewicz; Beata Bergler-Czop; Ligia Brzezińska-Wcisło
Journal:  Postepy Dermatol Alergol       Date:  2017-02-07       Impact factor: 1.837

7.  Associations between site of skin lesions and depression, social anxiety, body-related emotions and feelings of stigmatization in psoriasis patients.

Authors:  Patryk Łakuta; Kamil Marcinkiewicz; Beata Bergler-Czop; Ligia Brzezińska-Wcisło; Anna Słomian
Journal:  Postepy Dermatol Alergol       Date:  2018-02-20       Impact factor: 1.837

8.  Perception of Hair Loss and Education Increases the Treatment Willingness in Patients With Androgenetic Alopecica: A Population-Based Study.

Authors:  Bo-Kyung Kim; Solam Lee; Myeongsoo Jun; Hee-Chul Chung; Sung-Soo Oh; Won-Soo Lee
Journal:  Ann Dermatol       Date:  2018-06-27       Impact factor: 1.444

Review 9.  Oral fumaric acid esters for psoriasis.

Authors:  Ausama Atwan; John R Ingram; Rachel Abbott; Mark J Kelson; Timothy Pickles; Andrea Bauer; Vincent Piguet
Journal:  Cochrane Database Syst Rev       Date:  2015-08-10

10.  A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.

Authors:  A Blauvelt; K Papp; A Gottlieb; A Jarell; K Reich; C Maari; K B Gordon; L K Ferris; R G Langley; Y Tada; R G Lima; H Elmaraghy; G Gallo; L Renda; S Y Park; R Burge; J Bagel
Journal:  Br J Dermatol       Date:  2020-01-15       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.